Event Date/Time: Jul 21, 2011
End Date/Time: Jul 21, 2011
Biosimilar medicines are already a commercial reality in the European Union. The U.S. Healthcare Reform legislation â€“ with its distinct pathway for the regulatory approval of follow-on biologics â€“ should open up the U.S. market in the future, but in the intervening time, the next batch of biosimilars will face other difficulties in reaching the market, both in the EU and elsewhere. With many valuable second and third generation biological products remaining protected for several years to come by innovator patent estates, This event examines and discuss some of the patent issues that may occur during the development of biosimilar medicines for the EU market.